Mo1615 Targeting Fasl Increases the Anti-Tumor Immune Response in an In Vivo Model of Colon Cancer.

O’Callaghan, G. P., Ryan, A. E., Neary, P., O’Mahony, C., Shanahan, F., & Houston, A. (2012). Mo1615 Targeting Fasl Increases the Anti-Tumor Immune Response in an In Vivo Model of Colon Cancer. Gastroenterology, 142(5), S-642. https://doi.org/10.1016/s0016-5085(12)62470-6